



Please type a plus sign (+) inside this box → ☒

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Approved for use through: 10/31/2002, OMB 0591-0035

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

POWER OF ATTORNEY OR AUTHORIZATION OF AGENT

Application Number	10/005,983
Filing Date	October 31, 2001
First Named Inventor	Hans Josef Strauss
Title	NOVONOLAPLASTIC METHODS AND MOLECULES
Group Art Unit	1645
Employer Name	
Attorney Docket Number	ICI 103

I hereby appoint:

☐ Practitioners at Customer Number OR

☒ Practitioner(s) named below:

Place Customer
Number Bar Code
Label here

Name	Registration Number
Patricia L. Pabst	31,284
Zhaoyang Li	46,872
Rivka D. Monheit	48,731
Yang Xu	45,243

as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.

Please change the correspondence address for the above-identified application to:

☐ The above-mentioned Customer Number.

OR

☐ Practitioners at Customer Number

OR

Place Customer
Number Bar Code
Label here

☒ Firm or Individual Name Patricia L. Pabst; Holland & Knight LLP

Address Suite 2000, One Atlantic Center

Address 1201 West Peachtree Street, N.E.

City Atlanta

State GA

Zip 30309-3400

Country USA

Telephone (404) 817-8473

Fax (404) 817-8588

I am the:

☐ Applicant/Inventor.

☒ Assignee of record of the entire interest. See 37 CFR 3.71.
Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96).

SIGNATURE of Applicant or Assignee of Record

Name Imperial College Innovations Limited

Signature

Date

25/4/2002

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below.

Total of 1 forms are submitted.

Before Mail Statement: This form is submitted to the U.S. Patent and Trademark Office. This will vary depending upon the needs of the individual case. Any comments on the statement of form you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20221. DO NOT SEND FORMS OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20221.

COPY OF PAPERS
ORIGINALLY FILED

#9

ASSIGNMENT

We, Hans Josef Stauss of Imperial College School of Medicine, Hammersmith Hospital, Department of Immunology, Du Cane Road, London W12 0NN, UNITED KINGDOM, and Persis Jal Amrolia of Imperial College School of Medicine, Hammersmith Hospital, Department of Haematology, Du Cane Road, London W12 0NN, UNITED KINGDOM, in consideration of ten dollars and other valuable consideration paid to us by Imperial College Innovations Limited, a corporation of the UNITED KINGDOM, having its principal place of business at Sherfield Building, Imperial College London SW7 2ZA, UNITED KINGDOM, the receipt of which is hereby acknowledged, do hereby sell, assign and transfer unto said Imperial College Innovations Limited, its successors and assigns, the entire interest for the United States of America, and its territories and all foreign countries and jurisdictions, including all rights of priority under the International Convention for the Protection of Industrial Property, in a certain invention or improvement in "*Immunotherapeutic Methods and Molecules*" described in U.S. Serial No. 10/003,983 filed in the United States Patent and Trademark Office on October 31, 2001, by Hans Josef Stauss and Persis Jal Amrolia, which claims priority under 35 U.S.C. § 119 to International Application No. PCT/GB00/04566 filed in the United Kingdom Receiving Office for the Patent Cooperation Treaty on November 30, 2000, and in all Letters Patent of the United States and its territories and all foreign countries and jurisdictions which may or shall be granted on said invention, or any parts thereof, or on said application, or any provisional, divisional, continuation, continuation-in-part, reissue, or other applications based in whole or in part thereon. And we agree, for ourselves and our executors and administrators, with said corporation and its successors and assigns, but at its or their expense or charges, hereafter to execute all applications, amended specifications, deeds or other instruments, and to do all acts necessary or proper to secure the grant of Letters Patent in the United States and its territories and in all other foreign countries and jurisdictions to said corporation, with specifications and claims in such form as shall be approved by the counsel of said corporation, and to vest and confirm in said corporation, its successors and assigns, the legal title to all such patents.

DISK TO STFC

DATE: _____




COPY OF PAPERS
ORIGINALLY FILED

Title: "Immunotherapeutic Methods and Molecules"
By: Hans Josef Stauss and Persis Jal Amrolia
Filed: October 31, 2001
ASSIGNMENT

And we do hereby authorize and request the Commissioner of Patents and Trademarks of the United States to issue such Letters Patent as shall be granted upon said application or applications based thereon to said corporation, its successors and assigns.

WITNESS my hand and seal this 9th day of January, 2001. 2



Hans Josef Stauss

Witnesses:

1. Signed: Angelika Holler
Printed Name: ANGELIKA HOLLER
Address: 75 BIRCHMORE WALK
5N 2TL LONDON
2. Signed: G Cooke
Printed Name: GEORGE JONSTAN COOKE
Address: FLAT 13 NEWTON HOUSE, UNION GROVE
LONDON SW8 2RZ UK.

Title: "Immunotherapeutic Methods and Molecules"
By: Hans Josef Stauss and Persis Jal Amrolia
Filed: October 31, 2001
ASSIGNMENT

WITNESS my hand and seal this 24th day of January, 2002

P. Amrolia
Persis Jal Amrolia

Witnesses:

1. Signed: Martin Pulè
Printed Name: Martin Pulè
Address: Center for Cell and Gene Therapy, Houston, Texas 77030,
US.
2. Signed: Ettore Biagi
Printed Name: ETTORE BIAGI
Address: Center for Cell and Gene Therapy, Houston,
Texas - 77030. U.S.A

ATL1 #494281 v1

U.S.S.N.: 10/003,983

Filed: October 31, 2001

Response to Notice to Comply With Requirements for Patent Applications
Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures,
Amendment and Declaration under 37 C.F.R. § 1.821 (f)




Certificate of Mailing Under 37 C.F.R. § 1.8(a)

I hereby certify that this paper, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date shown below with sufficient postage as first-class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Date: July 18, 2002

ATL1 #526601 v1


Aisha Wyatt

COPY OF PAPERS
ORIGINALLY FILED



PTO/SB/98 (08-00)

Approved for use through 10/31/2002, OMB 0651-0031.
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1985, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)Applicant/Patent Owner: Hans Josef Stauss and Persis Jal AmroliaApplication No./Patent No.: 10/003,983 Filed/Issue Date: October 31, 2001Entitled: IMMUNOTHERAPEUTIC METHODS AND MOLECULESImperial College Innovations Limited, a United Kingdom Corporation

(Name of Assignee)

(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of less than the entire right, title and interest.
The extent (by, percentage) of its ownership interest is _____ %

in the patent application/patent identified above by virtue of either:

- A. ☐ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

OR

- B. ☐ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

1. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

2. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

3. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

- ☐ Copies of assignments or other documents in the chain of title are attached.

[NOTE: A separate copy (i.e., the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

25/4/2002
Date

S. Seale
Typed or printed name
[Signature]
Signature
25/4/2002 Director
Title

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

ICOWIP25417US ICI 103 078230100001

COPY OF PAPERS
ORIGINALLY FILED